You are here
ecancerTV interviews Hagop Kantarjian of MDACC.
This is a really interesting interview with Hagop Kantarjian of MDACC, Houston where he talks about the current therapies for CML. He has an interesting view on 2nd generation TKI in front line treatment and how that can be managed in the future given the increase in prevalence (patients living with cml) which will impact on the healthcare costs. He also has good things to say about patients with T315i mutation treated with ponatinib.
He has an interesting view on 2nd generation TKI in front line treatment and how that can be managed in the future given the increase in prevalence (patients living with cml) which will impact on the healthcare costs. He also has good things to say about patients with T315i mutation treated with ponatinib.
This is a must watch interview. Unfortunatel ecancer TV no longer provide an 'embed' code for individual video interviews... but there are lots of good interviews on there so you can pick and mix as you like.
http://www.ecancermedicalscience.com/tv/video-by-category.asp?play=1045&cid=1&scid=12&q=